Good day, everyone. My name is Mitchell, and I will be your conference operator today. At this time, I would like to welcome you to Kezar Life Sciences 2025 Topline Data Presentation of the PORTOLA ...
“Teclistamab appeared to show durable efficacy as rescue therapy across six different refractory autoimmune diseases,” the authors of the study wrote. “Further clinical trials are warranted to better ...
Kezar Life Sciences, Inc. (Nasdaq: KZR, the Company), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today ...
Autoimmune hepatitis (AIH) is a chronic, progressive liver disease caused by immune system dysregulation that targets the liver. If untreated, AIH can lead to severe complications, including cirrhosis ...
Tacrolimus binds to the intracellular protein FKBP12, forming a complex that specifically inhibits calcineurin, a protein phosphatase essential for activating the transcription factor NFAT. By ...
Autoimmune hepatitis (AIH) is a chronic, progressive liver disease caused by immune system dysregulation that targets the liver. If untreated, AIH can lead to severe complications, including cirrhosis ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Kezar Life Sciences, Inc (KZR). (Nasdaq: KZR, the Company), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback